{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:35:06Z","timestamp":1788233706033,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2018.11.007","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T14:04:03Z","timestamp":1544105043000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Current treatment strategies in refractory chronic pruritus"],"prefix":"10.1016","volume":"46","author":[{"given":"Manuel Pedro","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asit","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0010","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.1097\/itx.0000000000000006","article-title":"Management of chronic pruritus: from the dermatological office to the specialized itch center. A review","volume":"2","author":"Pereira","year":"2017","journal-title":"Itch"},{"key":"10.1016\/j.coph.2018.11.007_bib0015","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/ddg.13304_g","article-title":"S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion","volume":"15","author":"Stander","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.coph.2018.11.007_sbref0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/00015555-1400","article-title":"European guideline on chronic pruritus","volume":"92","author":"Weisshaar","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.11.007_sbref0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.11.007_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","article-title":"Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor","volume":"98","author":"Yosipovitch","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.11.007_bib0035","first-page":"172","article-title":"Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies","volume":"15","author":"Draelos","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.11.007_sbref0050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0055","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.11.007_bib0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/aap.2017.38.4080","article-title":"Interleukin 31 and skin diseases: a systematic review","volume":"38","author":"Gangemi","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.coph.2018.11.007_bib0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.11.007_bib0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_sbref0075","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.11.007_bib0080","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/j.pain.0000000000000172","article-title":"A central role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch","volume":"156","author":"Akiyama","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.coph.2018.11.007_bib0090","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"Stander","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2018.11.007_bib0095","article-title":"A systematic review of evidence-based treatments for prurigo nodularis","author":"Qureshi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0100","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s13555-016-0122-9","article-title":"A review of the efficacy of thalidomide and lenalidomide in the treatment of refractory prurigo nodularis","volume":"6","author":"Lim","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.coph.2018.11.007_bib0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.semnephrol.2015.06.009","article-title":"Pruritus in kidney disease","volume":"35","author":"Combs","year":"2015","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.coph.2018.11.007_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-200969030-00002","article-title":"Uraemic pruritus: clinical characteristics, pathophysiology and treatment","volume":"69","author":"Manenti","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2018.11.007_bib0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1526-0968.2004.00175.x","article-title":"Effect of skin care with an emollient containing a high water content on mild uremic pruritus","volume":"8","author":"Okada","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.coph.2018.11.007_bib0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09546630802441218","article-title":"A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients","volume":"20","author":"Young","year":"2009","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.coph.2018.11.007_bib0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5414\/CP201629","article-title":"Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients","volume":"50","author":"Feily","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.11.007_bib0130","first-page":"137","article-title":"Topical capsaicin therapy for uremic pruritus in patients on hemodialysis","volume":"4","author":"Makhlough","year":"2010","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.coph.2018.11.007_bib0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2006.03.082","article-title":"Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus","volume":"48","author":"Chen","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.coph.2018.11.007_bib0140","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1346-8138.12895","article-title":"Effect of topical vitamin D on chronic kidney disease-associated pruritus: an open-label pilot study","volume":"42","author":"Jung","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1774-9987.2005.00271.x","article-title":"Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options","volume":"9","author":"Szepietowski","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.coph.2018.11.007_bib0150","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2004.08.050","article-title":"Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study","volume":"52","author":"Duque","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0155","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1365-4362.1991.tb04360.x","article-title":"Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus","volume":"30","author":"Francos","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.7326\/0003-4819-93-3-446","article-title":"Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal","volume":"93","author":"Pederson","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2018.11.007_bib0165","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.1.6063.752","article-title":"Cholestyramine in uraemic pruritus","volume":"1","author":"Silverberg","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.coph.2018.11.007_bib0170","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1155\/2014\/410415","article-title":"Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study","volume":"19","author":"Bittencourt da Silva","year":"2014","journal-title":"Pain Res Manag"},{"key":"10.1016\/j.coph.2018.11.007_bib0175","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1093\/ndt\/gfm343","article-title":"Pentoxifylline as treatment for uraemic pruritus\u2013an addition to the weak armentarium for a common clinical symptom?","volume":"22","author":"Mettang","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2018.11.007_sbref0180","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/09546634.2016.1161161","article-title":"Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature","volume":"27","author":"Nofal","year":"2016","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.coph.2018.11.007_bib0185","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/hdi.12455","article-title":"Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial","volume":"21","author":"Foroutan","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.coph.2018.11.007_bib0190","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/jpm.2012.0504","article-title":"Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients","volume":"16","author":"Chan","year":"2013","journal-title":"J Palliat Med"},{"key":"10.1016\/j.coph.2018.11.007_bib0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.coph.2018.11.007_bib0200","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.coph.2018.11.007_bib0205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1681\/ASN.V113514","article-title":"Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study","volume":"11","author":"Pauli-Magnus","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coph.2018.11.007_bib0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.16117","article-title":"British Association of Dermatologists\u2019 guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018","volume":"178","author":"Millington","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.11.007_bib0215","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"Al-Dury","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.coph.2018.11.007_sbref0220","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.coph.2018.11.007_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/hepr.12894","article-title":"Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride","volume":"48","author":"Akuta","year":"2018","journal-title":"Hepatol Res"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:48:48Z","timestamp":1761461328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":45,"alternative-id":["S1471489218301280"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.11.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment strategies in refractory chronic pruritus","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}